Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $40.00 price objective on the biotechnology company’s stock.

A number of other research firms have also weighed in on CAPR. Maxim Group reaffirmed a buy rating and set a $12.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, September 17th. Cantor Fitzgerald restated an overweight rating and set a $8.00 price target on shares of Capricor Therapeutics in a report on Friday, September 20th. Finally, Oppenheimer reiterated an outperform rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $22.60.

Capricor Therapeutics Trading Down 0.4 %

Shares of CAPR opened at $9.95 on Tuesday. The company’s 50-day moving average price is $4.80 and its 200 day moving average price is $5.31. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $12.87. The firm has a market cap of $318.19 million, a P/E ratio of -11.44 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. Equities research analysts forecast that Capricor Therapeutics will post -1.14 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. The purchase was disclosed in a filing with the SEC, which is available at this link. 12.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in CAPR. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics during the second quarter worth about $426,000. Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the period. Finally, Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics during the 2nd quarter valued at about $147,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.